HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prestige Consumer Healthcare Grows International Sales 8%, Citing Hydralyte Expansion

Executive Summary

Prestige Consumer Healthcare’s Hydralyte sales grew in excess of 20% fiscal year-to-date in key market Australia, reflecting PCH’s work to expand the brand’s appeal from a vomiting and diarrhea treatment to a sports and general hydration drink. Hydralyte is PCH’s biggest brand in Australia where the name is “synonymous with oral hydration,” company leadership says.

You may also be interested in...



Dentek Destocking Takes Bite Off Prestige Topline Despite Brand-Building

Dentek oral care brand struggles with retailer destocking as Prestige Consumer Healthcare continues brand-building including working with retailers to expand inventory and running TV campaigns on nighttime teeth grinding. Firm reports net sells fell 8.6% in its latest quarter.

Prestige Brands Invests $111m To Boost Advertising From Market Research

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

Bausch Expects US Approval In 2020 Of Preservative-Free OTC Ketotifen Eye Drop

Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel